| Autor: |
Reznikov K. M., Gorbunova N. S., Kolesnichenko P. D., Tverskoy A. V., Kostina D. A., Bashkatova D. A., Nikitina V. A. |
| Předmět: |
|
| Zdroj: |
Research Results in Pharmacology; 2017, Vol. 3 Issue 1, p125-136, 12p |
| Abstrakt: |
The article contains the analysis of medical and biological publications from the global database created by the National Centre for Biology Information (NCBI), an intramural biotechnological division of the US National Library of Medicine. The authors have analyzed publications of the recent ten years. Major results of study of erythropoietins and their recombinant analogues have been generalized and systematized. There has been revealed the significant potential of the preparations of this group to be studied and used. Major advantages and drawbacks of erythropoietins and their recombinant analogues have been described. It has been pointed out that a great variety of erythropoietins and darbepoetins speaks to the fact that there is lack of "universe" erythropoietin meeting all the requirements. Genetically modified erythropoietin having both -- pharmacokinetics convenient for clinical application and all properties of the natural analogue -- is considered to be the most successful darbepoetin. This property has been resulted from the fact that comparing to standard erythropoietin darbepoetin has bigger molecular weight due to introduction of 2 complementary sites of glycosylation. This, in turn, results in the increase of half-life period and, consequently, decreases application frequency of the preparation that makes it more convenient to use comparing to erythropoietin. Application of erythropoietin and its derivatives in stroke therapy in experimental animal models undoubtedly has positive impact on the reduction of the infarction size and dynamics of recovery of neurological status. Results of the analysis demonstrate that the studied preparations are more effective in the early period following stroke than being applied in the later hours. However, there has been revealed some insufficient knowledge in treatment of brain ischemic lesions and ischemic heart disease. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
